Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rabies Clear all
Completed Phase 2 Interventional

Increasing HAART-Induced Immune Restoration With Cyclosporine

NCT00031070
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
15
States / cities
Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Responses to Rabies Vaccine in Adults With or Without Antibiotics

NCT03557008
View directory record Official record
Conditions
Rabies Human
Interventions
Rabies Vaccine, Metronidazole, Vancomycin, Neomycin Sulfate
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

NCT04062669
View directory record Official record
Conditions
Virus Diseases
Interventions
Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Saline Placebo, RabAvert
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety of Three Experimental HIV Vaccines

NCT00000946
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
HIV p24/MF59 Vaccine, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2001
U.S. locations
7
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

NCT03264157
View directory record Official record
Conditions
Healthy
Interventions
HRIG, HyperRAB, RabAvert
Drug · Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Saint Paul, Minnesota • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

NCT04019444
View directory record Official record
Conditions
Rabies, Rabies Immunisation
Interventions
ChAd155-RG, Placebo, Rabies Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines

NCT02956746
View directory record Official record
Conditions
Human Rabies
Interventions
SYN023, Imovax, RabAvert, HyperRAB ST (human rabies immune globulin)
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 20, 2026, 5:37 PM EDT
Terminated Phase 4 Interventional

Antibody Production in Immune Disorders

NCT00023504
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Pneumovax, Rabavert, Prevnar, Tetanus diphtheria toxoid
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

NCT00001076
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

NCT00000847
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis

NCT02374814
View directory record Official record
Conditions
Rabies
Interventions
Rabies vaccine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Not applicable Interventional

Improving Adherence to Rabies PEP Guideline Recommendations

NCT04213950
View directory record Official record
Conditions
Rabies, Rabies Human, Rabies Virus Infection
Interventions
Rabies PEP quality improvement bundle
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Baytown, Texas • Cypress, Texas • Houston, Texas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine Responsiveness After CAR-T Cell Therapy

NCT04410900
View directory record Official record
Conditions
B-Cell Neoplasm
Interventions
Wistar Rabies Virus Strain PM-1503-3M Vaccine, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

NCT00001055
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects

NCT00656097
View directory record Official record
Conditions
Rabies
Interventions
CL184, HRIG, Placebo matching CL184
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
19 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

NCT02040090
View directory record Official record
Conditions
Rabies
Interventions
Active rabies vaccine (US-FDA approved)
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies

NCT02912845
View directory record Official record
Conditions
Rabies
Interventions
KamRAB - HRIG
Drug
Lead sponsor
Kamada, Ltd.
Industry
Eligibility
0 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Community Interventions to Eliminate Neglected Tropical Diseases

NCT03667079
View directory record Official record
Conditions
Rabies in Animals, Worms; Intestine
Interventions
integrated delivery of deworming and vaccination, Mass deworming only, Mass vaccination of dogs
Other
Lead sponsor
Washington State University
Other
Eligibility
Not listed
Enrollment
28,143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

NCT01877395
View directory record Official record
Conditions
Rabies
Interventions
Purified Vero Rabies Vaccine (VRVg), Imovax® Rabies: inactivated rabies vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Pembroke Pines, Florida • South Miami, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

NCT03145766
View directory record Official record
Conditions
Rabies Virus
Interventions
VRVg 2, VRVg 1, Imovax Rabies, Human Rabies Immunoglobulins (HRIG)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Redding, California • San Diego, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 20, 2026, 5:37 PM EDT
Terminated No phase listed Observational

Survey of Human Rabies Immune Globulin Safety in Children

NCT05382650
View directory record Official record
Conditions
Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
Interventions
Human rabies immune globulin 300 IU/mL
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
Up to 17 Years
Enrollment
35 participants
Timeline
2023 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 20, 2026, 5:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

NCT04056117
View directory record Official record
Conditions
Shigellosis
Interventions
Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo
Biological
Lead sponsor
LimmaTech Biologics AG
Industry
Eligibility
8 Months to 50 Years
Enrollment
597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 5:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rabies Immune Plasma Booster Study

NCT01063140
View directory record Official record
Conditions
Rabies
Interventions
Rabies Vaccine (RabAvert), Rabies Vaccine (Imovax)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Tempe, Arizona • Rock Island, Illinois • Oak Park, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 20, 2026, 5:37 PM EDT